First Mover
Lipocyte BioMed pioneers medicine based on mRNAs of the subcutaneous adipose tissue. Since 2014 we develop technologies and solutions for personalised medicine of metabolic diseases.
Our platform technology enables the quick and efficient coining of new products and applications for further diseases.
Breaking new ground for
diagnostics, therapeutics and prevention
Diagnostics
mRNA-analysis of the SAT offers deep and completely new insights into the energy metabolism. Especially with metabolic diseases the current dynamics of the body and influences over life-time play a far greater role than genetic dispositions
Read moreTherapeutics
The key to successful treatment of metabolic diseases lies in the intervention with disease-causing on-going biological processes. As the mRNA of the SAT are to a great extent the drivers of pathology of these diseases, they offer a strong lever for therapy.
Read morePrevention
A great advantage of mRNA-analysis of the subcutaneous adipose tissue lies in the very early detection of unhealthy developments of the metabolism long before any signs can be seen in blood-analysis or any symptoms become apparent. It is, therefore, a powerful component in preventive personalised medicine.
Read more